Compare Adaptive Biotechnologies Corp (ADPT) vs Simon Property Group Inc (SPG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Simon Property Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Simon Property Group Inc trades at $219.75 (market cap $73.68B). The key difference: Simon Property Group Inc is far larger — about 22.1× Adaptive Biotechnologies Corp's market cap, and Simon Property Group Inc pays a 3.87% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SPG | |
|---|---|---|
Market Cap | $3.33B | $73.68B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $227.56 |
52-Week Low | $10.24 | $159.93 |
Enterprise Value | $3.19B | $102.16B |
Dividend Yield | — | 3.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Simon Property Group (SPG) trades at $227.19, up 0.5% on the day, with strong technical momentum as the stock approaches key resistance near $228. The REIT demonstrates robust fundamentals with Q1 2026 earnings beating expectations, revenue growth accelerating to $6.36B in 2025, and exceptional profitability metrics including 70.59% net income margin and 127.05% ROE. Recent corporate developments include a $2.25 dividend payment and Euro-denominated note offering, while analyst sentiment remains mixed despite strong operational performance.
SPG presents a compelling investment case with premium mall assets generating strong cash flows and dividend income, though elevated valuation multiples and significant debt levels warrant caution. The stock's current price above the $211.30 consensus target suggests limited near-term upside, while e-commerce competition and interest rate sensitivity represent ongoing headwinds for the retail REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
